ETD001 multiple once daily doses ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 299 | 嚢胞性線維症 | 1 |
299. 嚢胞性線維症
臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04926701 (ClinicalTrials.gov) | June 11, 2021 | 10/6/2021 | A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects | A First in Human Randomised, Double Blind, Placebo-controlled, Two-part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD and MAD) of Inhaled ETD001 in Healthy Male and Female Subjects | Cystic Fibrosis | Drug: ETD001 single dose;Drug: Placebo single dose;Drug: ETD001 multiple twice daily doses;Drug: Placebo multiple twice daily doses;Drug: ETD001 multiple once daily doses;Drug: Placebo multiple once daily doses | Enterprise Therapeutics Ltd | NULL | Active, not recruiting | 18 Years | 50 Years | All | 98 | Phase 1 | United Kingdom |